Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.

Diabetes, obesity & metabolism·2026
Same author

Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight.

Advances in therapy·2026
Same author

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Nature medicine·2026
Same author

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation·2026
Same author

Cumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study.

PloS one·2026
Same journal

The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.

Current atherosclerosis reports·2026
Same journal

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same journal

Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

Current atherosclerosis reports·2026
Same journal

Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

Current atherosclerosis reports·2026
Same journal

Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

Current atherosclerosis reports·2026
Same journal

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Pharmacotherapy for obesity.

Lisa M Neff1, Louis J Aronne

  • 1Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, Rockefeller University Hospital, 1230 York Avenue, Box 332, New York, NY 10021, USA. LNeff@Rockefeller.edu

Current Atherosclerosis Reports
|April 2, 2008
PubMed
Summary
This summary is machine-generated.

Obesity affects one-third of American adults. Modest weight loss through lifestyle changes and pharmacotherapy significantly improves associated conditions like diabetes and hypertension, with new drug targets emerging.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Area of Science:

  • Metabolic Disorders
  • Endocrinology
  • Pharmacology

Background:

  • Obesity is a prevalent chronic metabolic disorder affecting a significant portion of the adult population.
  • Obesity is linked to numerous co-morbidities, including dyslipidemia, hypertension, and type 2 diabetes.
  • Even modest weight loss (5%-10%) yields substantial health benefits.

Purpose of the Study:

  • To review the indications and goals for obesity pharmacotherapy.
  • To examine current and future pharmacologic strategies for obesity treatment.
  • To highlight novel drug targets based on endocrine pathways regulating body weight.

Main Methods:

  • Review of current literature on obesity pharmacotherapy.
  • Analysis of endocrine pathways involved in body weight regulation.
  • Identification of potential targets for antiobesity drug development.

Main Results:

  • Current pharmacologic treatments for obesity are limited.
  • Advances in understanding endocrine pathways offer new avenues for drug development.
  • Key targets include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones.

Conclusions:

  • Pharmacotherapy plays a role in managing obesity and its co-morbidities.
  • Further research into endocrine pathways is crucial for developing effective antiobesity medications.
  • Targeting specific hormones presents a promising future for obesity treatment.